Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

Jordan, De Bennett, Ma Wainberg, D Havlir, S Hammer, C Yang, L Morris, M Peeters, Am Wensing, N Parkin, Jb Nachega, A Phillips, Andrea De Luca, E Geng, A Calmy, E Raizes, P Sandstrom, Cp Archibald, J Perriëns, Cm McclureSy Hong, Jh Mcmahon, N Dedes, D Sutherland, S. Bertagnolio

Risultato della ricerca: Contributo in rivistaArticolo in rivista

47 Citazioni (Scopus)


The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
Lingua originaleEnglish
pagine (da-a)S245-S245-9
RivistaClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume54 Suppl 4
Stato di pubblicazionePubblicato - 2012


  • Anti-Retroviral Agents
  • Developing Countries
  • Drug Resistance, Viral
  • HIV Infections
  • Health Policy
  • Health Surveys
  • Humans
  • World Health
  • World Health Organization


Entra nei temi di ricerca di 'Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011'. Insieme formano una fingerprint unica.

Cita questo